Drug intelligence / Profile preview

nks01

Development stage: Discontinued
Lead developer: Megmilk Snow Brand
Modality: Small Molecules
Administration: Unspecified

Overview

NKS01 is a **small-molecule aromatase inhibitor** that was being developed primarily by Snow Brand Milk Products and later by Nippon Kayaku for the treatment of **breast cancer** and related hormone-dependent disorders. Aromatase inhibitors block the conversion of androgens to estrogens by inhibiting the aromatase enzyme, thereby reducing estrogen levels—which is beneficial in treating estrogen receptor-positive breast cancer. NKS01 is also known by the synonym 14alphaOHAT. The drug development was discontinued after phase II trials for breast cancer.

Targets

CYP19A1 (Aromatase)

Beyond the preview

Go deeper on nks01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nks01.

Explore the full profile